These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

690 related articles for article (PubMed ID: 11849789)

  • 21. Treatment results of adjuvant radiotherapy and salvage radiotherapy after radical prostatectomy for prostate cancer.
    Wadasaki K; Kaneyasu Y; Kenjo M; Matsuura K; Murakami Y; Hashimoto Y; Ito K; Kiriu H; Ito A
    Int J Clin Oncol; 2007 Feb; 12(1):37-41. PubMed ID: 17380439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radical prostatectomy and postoperative irradiation in patients with pathological stage C (T3) carcinoma of the prostate.
    Petrovich Z; Lieskovsky G; Langholz B; Formenti S; Baert L; Streeter O; Skinner DG
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):139-47. PubMed ID: 9422570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7.
    D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Tomaszewski JE; Wein A
    Cancer; 2000 May; 88(9):2110-5. PubMed ID: 10813723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant and salvage radiotherapy after radical prostatectomy.
    Höcht S; Wiegel T; Schostak M; Hinkelbein W
    Onkologie; 2002 Jun; 25(3):201-6. PubMed ID: 12119453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years.
    Anscher MS; Clough R; Dodge R
    Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):369-75. PubMed ID: 10974449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
    Kneebone A; Fraser-Browne C; Duchesne GM; Fisher R; Frydenberg M; Herschtal A; Williams SG; Brown C; Delprado W; Haworth A; Joseph DJ; Martin JM; Matthews JHL; Millar JL; Sidhom M; Spry N; Tang CI; Turner S; Wiltshire KL; Woo HH; Davis ID; Lim TS; Pearse M
    Lancet Oncol; 2020 Oct; 21(10):1331-1340. PubMed ID: 33002437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins.
    Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P; Pearse M
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):407-12. PubMed ID: 19211197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: analysis of freedom from PSA failure.
    Zietman AL; Coen JJ; Shipley WU; Althausen AF
    Urology; 1993 Sep; 42(3):292-8; discussion 298-9. PubMed ID: 7691014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer.
    Vicini FA; Ziaja EL; Kestin LL; Brabbins DS; Stromberg JS; Gonzalez JA; Martinez AA
    Urology; 1999 Jul; 54(1):111-7. PubMed ID: 10414736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors.
    Bloom KD; Richie JP; Schultz D; Renshaw A; Saegaert T; D'amico AV
    Urology; 2004 Feb; 63(2):333-6. PubMed ID: 14972484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy.
    Coetzee LJ; Hars V; Paulson DF
    Urology; 1996 Feb; 47(2):232-5. PubMed ID: 8607240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The results of radical prostatectomy at a community hospital during the prostate specific antigen era.
    Smitt MC; Heltzel M
    Cancer; 1996 Mar; 77(5):928-33. PubMed ID: 8608486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preliminary results of three-dimensional conformal radiotherapy as salvage treatment for a rising prostate-specific antigen level postprostatectomy.
    Wilder RB; Hsiang JY; Ji M; Earle JD; de Vere White R
    Am J Clin Oncol; 2000 Apr; 23(2):176-80. PubMed ID: 10776980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
    Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update.
    Anscher MS; Robertson CN; Prosnitz R
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):37-43. PubMed ID: 7543893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.
    Parker CC; Clarke NW; Cook AD; Kynaston HG; Petersen PM; Catton C; Cross W; Logue J; Parulekar W; Payne H; Persad R; Pickering H; Saad F; Anderson J; Bahl A; Bottomley D; Brasso K; Chahal R; Cooke PW; Eddy B; Gibbs S; Goh C; Gujral S; Heath C; Henderson A; Jaganathan R; Jakobsen H; James ND; Kanaga Sundaram S; Lees K; Lester J; Lindberg H; Money-Kyrle J; Morris S; O'Sullivan J; Ostler P; Owen L; Patel P; Pope A; Popert R; Raman R; Røder MA; Sayers I; Simms M; Wilson J; Zarkar A; Parmar MKB; Sydes MR
    Lancet; 2020 Oct; 396(10260):1413-1421. PubMed ID: 33002429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors].
    Feyaerts A; Delrée A; Lorge F; Opsomer RJ; Wese FX; Van Cangh PJ; Draguet AP; Cosyns JP
    Acta Urol Belg; 1997 Mar; 65(1):11-8. PubMed ID: 9245198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
    Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
    J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.